Integral Health Asset Management LLC Raises Position in Quest Diagnostics Incorporated (NYSE:DGX)

Integral Health Asset Management LLC raised its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 8.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 130,000 shares of the medical research company's stock after buying an additional 10,000 shares during the period. Quest Diagnostics comprises approximately 1.7% of Integral Health Asset Management LLC's investment portfolio, making the stock its 19th biggest position. Integral Health Asset Management LLC owned 0.12% of Quest Diagnostics worth $19,612,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of DGX. Meiji Yasuda Asset Management Co Ltd. boosted its stake in shares of Quest Diagnostics by 1.6% during the 4th quarter. Meiji Yasuda Asset Management Co Ltd. now owns 3,843 shares of the medical research company's stock worth $580,000 after acquiring an additional 60 shares in the last quarter. Net Worth Advisory Group boosted its stake in shares of Quest Diagnostics by 1.0% during the 4th quarter. Net Worth Advisory Group now owns 6,495 shares of the medical research company's stock worth $980,000 after acquiring an additional 62 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of Quest Diagnostics by 0.3% during the 4th quarter. Bessemer Group Inc. now owns 20,811 shares of the medical research company's stock worth $3,140,000 after acquiring an additional 65 shares in the last quarter. Brooklyn Investment Group boosted its stake in shares of Quest Diagnostics by 5.5% during the 4th quarter. Brooklyn Investment Group now owns 1,315 shares of the medical research company's stock worth $198,000 after acquiring an additional 68 shares in the last quarter. Finally, Mather Group LLC. boosted its stake in shares of Quest Diagnostics by 10.4% during the 4th quarter. Mather Group LLC. now owns 764 shares of the medical research company's stock worth $115,000 after acquiring an additional 72 shares in the last quarter. Hedge funds and other institutional investors own 88.06% of the company's stock.

Quest Diagnostics Price Performance

DGX stock traded down $2.22 during mid-day trading on Wednesday, reaching $172.27. The company's stock had a trading volume of 1,333,815 shares, compared to its average volume of 978,970. The stock has a market cap of $19.23 billion, a PE ratio of 22.40, a P/E/G ratio of 2.16 and a beta of 0.52. The company has a current ratio of 1.10, a quick ratio of 1.02 and a debt-to-equity ratio of 0.82. Quest Diagnostics Incorporated has a fifty-two week low of $135.47 and a fifty-two week high of $179.32. The company's 50 day moving average is $169.84 and its two-hundred day moving average is $163.19.

Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.15 by $0.06. The business had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.63 billion. Quest Diagnostics had a net margin of 8.80% and a return on equity of 15.07%. Equities research analysts expect that Quest Diagnostics Incorporated will post 9.7 EPS for the current year.

Quest Diagnostics Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, July 21st. Stockholders of record on Monday, July 7th will be issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.86%. Quest Diagnostics's dividend payout ratio is currently 40.46%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Evercore ISI increased their target price on shares of Quest Diagnostics from $175.00 to $180.00 and gave the stock an "in-line" rating in a research note on Wednesday, April 23rd. UBS Group increased their target price on shares of Quest Diagnostics from $166.00 to $170.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. StockNews.com lowered shares of Quest Diagnostics from a "buy" rating to a "hold" rating in a research note on Thursday, February 6th. Citigroup lowered shares of Quest Diagnostics from a "buy" rating to a "neutral" rating and set a $185.00 price target on the stock. in a research note on Tuesday, March 4th. Finally, Robert W. Baird raised their price target on shares of Quest Diagnostics from $191.00 to $194.00 and gave the company an "outperform" rating in a research note on Wednesday, April 23rd. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $185.73.

Insider Transactions at Quest Diagnostics

In related news, EVP Catherine T. Doherty sold 535 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $169.71, for a total transaction of $90,794.85. Following the completion of the transaction, the executive vice president now owns 71,356 shares of the company's stock, valued at approximately $12,109,826.76. This trade represents a 0.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael E. Prevoznik sold 528 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $172.61, for a total transaction of $91,138.08. Following the transaction, the senior vice president now directly owns 39,031 shares of the company's stock, valued at $6,737,140.91. The trade was a 1.33% decrease in their position. The disclosure for this sale can be found here. Insiders sold 55,124 shares of company stock worth $9,341,875 in the last 90 days. Insiders own 8.16% of the company's stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.